Soleno Therapeutics (SLNO) Shares Outstanding (2013 - 2026)

Soleno Therapeutics (SLNO) has 7 years of Shares Outstanding (Entity) data on file, last reported at $16.5 million in Q4 2023.

• On a quarterly basis, Shares Outstanding (Entity) rose 102.12% year-over-year to $16.5 million in Q4 2023; TTM through Dec 2023 was $16.5 million, a 102.12% increase from a year earlier, with the FY2023 full-year figure at $16.5 million, up 102.12% from the prior year.
• Shares Outstanding (Entity) for Q4 2023 stood at $16.5 million, up from $11.4 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for SLNO reached as high as $16.5 million in Q4 2023 and fell as low as $2.1 million in Q1 2019.
• Historically, Shares Outstanding (Entity) has averaged $6.0 million across 5 years, with a median of $5.3 million in 2021.
• Across the five-year window, Shares Outstanding (Entity) surged 150.35% in 2020 and advanced 0.27% in 2021, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $2.3 million in 2019, then soared by 83.41% to $4.2 million in 2020, then grew by 27.54% to $5.3 million in 2021, then soared by 53.24% to $8.2 million in 2022, then surged by 102.12% to $16.5 million in 2023.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $16.5 million in Q4 2023, $11.4 million in Q3 2023, and $9.1 million in Q2 2023.